Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372495 | 1.00 | GRIK1 (0.43) | GRIK1GRIK2CES2CES1HDAC8 | |
| SCHEMBL43790 | 1.00 | GRIK1 (0.43) | GRIK1GRIK2CES2CES1HDAC8 | |
| SCHEMBL7159243 | 0.98 | GRIK1 (0.44) | GRIK1GRIK2CES2CES1HDAC8 | |
| SCHEMBL16528332 | 0.98 | GRIK1 (0.44) | GRIK1GRIK2CES2CES1HDAC8 | |
| SCHEMBL865420 | 0.98 | GRIK1 (0.44) | GRIK1GRIK2CES2CES1HDAC8 | |
| Acrylic Acid SCHEMBL4943661 | 0.90 | LMNA (0.39) | GRIK1GRIK2CES2CES1LMNA | |
| Methacrylic Acid SCHEMBL1454970 | 0.88 | GRIK1 (0.37) | GRIK1GRIK2CES2CES1 | |
| SCHEMBL15927942 | 0.87 | GRIK1 (0.39) | GRIK1GRIK2CES2CES1TSHR | |
| SCHEMBL29013577 | 0.81 | CES2 (0.46) | GRIK1GRIK2CES2CES1HDAC8 | |
| SCHEMBL22164155 | 0.78 | CES2 (0.42) | CES2CES1HDAC8HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | GRIK1 2255/4885GRIK2 2664/4885CES2 400/4885 |
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | GRIK1 4072/4885GRIK2 4385/4885CES2 557/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | GRIK1 2469/4885GRIK2 2749/4885CES2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.